Alivus Life Sciences Ltd Share Price

Q: What is the share price of Alivus Life Sciences Ltd today?

Alivus Life Sciences Ltd share price as on 20 Mar 2025 is ₹1133.4

Pharmaceuticals

NSE: ALIVUS Small Cap ISIN: INE03Q201024

As on 20 March 2025 at 20:20 IST

₹1,133.40

+ 52.85

(4.89%)

Sell Buy

Over 1 Month

6.65%

Over 6 Months

-9.11%

Over 1 Year

48.32%

Over 3 Years

134.42%

Alivus Life Sciences Ltd Summary

Close ₹1,133.40

Open ₹1,098

High ₹1,136.80

Low ₹1,075.35

Volume 70,627

Net Turnover (in Cr) ₹7.89

52Wk High ₹1,335.10

52Wk Low ₹719.75

52Wk High / Low

719.75

1,335.10

Alivus Life Sciences Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹13,888.35

EPS (TTM) 36.05

Book Value (BV) 207.16

Div. Yield 1.99 %

P/E (TTM) 31.43

Price/Book Value 5.47

Delivery % 43.36 %

Face Value 2

Key Ratios

PE Ratio 20.17

PB Ratio 4.07

EV to Sales 4.04

PEG Ratio 24.02

ROA 19.91

ROE 21.07

Debt-Equity 0.01

Net Profit Margin 20.62

Operating Profit Margin 30.06

Alivus Life Sciences Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

No data available

Balance Sheet

No data available

Cash Flow

No data available

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,295.26	2,190.18	2,137.92	1,885.98	1,549.30
Total Expenses	1,663.97	1,561.57	1,572.99	1,415.03	1,128.24
Profit Before Tax	631.29	628.61	564.92	470.94	421.07
Profit After Tax	470.89	466.96	418.72	351.58	313.10
Operating Profit after Depreciation	632.84	629.16	592.89	558.49	454.58

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	809.87	792.89	595.03	572.80	546.25
Total Non Current Assets	934.41	851.81	706.42	598.03	565.49
Total Current Assets	1,916	1,850.34	1,764.58	1,399.04	1,160.11
TOTAL ASSETS	2,850.41	2,702.15	2,471.01	1,997.08	1,725.60
Total Shareholder's Fund	2,332.32	2,138.21	2,054.31	752.75	401.69

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	413.52	306.01	597.59	388.11	195.01
Net Cash used in Investing Activities	-116.48	-146.75	-122.23	-68.73	-50.52
Net Cash used in Financing Activities	-279.44	-387.59	-78.80	-213.78	-136.55

No data available

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	641.84	506.88	588.62	536.60	572.80
Total Expenses	451.54	372.52	429.13	395.16	400.25
Profit Before Tax	185.14	127.46	150.24	129.68	160.67
Profit After Tax	136.96	95.32	111.48	97.94	118.77
Operating Profit after Depreciation	200.76	142.89	164.98	144.57	174.24

Alivus Life Sciences Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,060.40

S2 1,040.25

S3 1,014.70

Pivot 1,085.95

R1 1,106.10

R2 1,131.65

R3 1,151.80

Moving Average

20 SMA 1,010.01

50 SMA 1,074.93

100 SMA 1,059.58

200 SMA 1,028.40

Alivus Life Sciences Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

AGM Date: 26 Sep 2022

AGM 26/09/2022 Further to our letter dated August 23, 2022 and pursuant to Regulation 30 of the Listing Regulations, enclosed please find herewith the Notice and Explanatory statement Convening the 11th Annual General Meeting (AGM) scheduled to be held on Monday, September 26, 2022 at 2.00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The notice of AGM is being sent to all the members whose email Ids have been registered with the Company. The Company is pleased to provide to its members the facility to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means. Only Shareholders, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e. Monday, September 19, 2022, shall be entitled to avail thee-voting facility. Submission of Annual Report under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 30/08/2022) Proceedings and Scrutinizer's Report of the 11th Annual General Meeting (AGM) of Glenmark Life Sciences Limited ('the Company') held on September 26, 2022 Proceedings and Scrutinizer's Report of the 11th Annual General Meeting (AGM) of Glenmark Life Sciences Limited ('the Company') held on September 26, 2022 (As Per BSE Announcement Dated on 26.09.2022)

AGM Date: 26 Sep 2023

AGM 26/09/2023 Intimation of Book Closure (As Per BSE Announcement Dated on 04/09/2023) Proceedings and Scrutinizer Report of 12th Annual General Meeting is attached (As Per BSE Announcement Dated on 26/09/2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 Please find attached herewith proceedings of 13th Annual General Meeting. (As per BSE Announcement Dated on 25/09/2024)

Alivus Life Sciences Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceuticals Industries Ltd	₹1,750.10	₹4,19,907.61
Divis Laboratories Ltd	₹5,823.70	₹1,54,600.94
Cipla Ltd	₹1,513.05	₹1,22,196.18
Torrent Pharmaceuticals Ltd	₹3,229.90	₹1,09,309.58
Dr Reddys Laboratories Ltd	₹1,186.65	₹99,020.65

Alivus Life Sciences Ltd Top Mutal Funds Invested

Fund Name	AUM
Quant Flexi Cap Fund	1.56%
Tata Small Cap Fund	0.67%
Quant Small Cap Fund	0.20%
Quant Business Cycle Fund	3.78%
Old Bridge Focused Equity Fund	2.74%

Alivus Life Sciences Ltd News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Alivus Life Sciences rallied 4.95% to Rs 1,178.25 after the company's consolidated revenue jumped 15.33% to Rs 136.96 crore on 12.05% increase in revenue from operations to Rs 641.84 crore in Q3 FY25 over Q3 FY24.

23 Jan 2025, 03:01 pm

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.

21 Jan 2025, 12:00 pm

Glenmark Life Sciences renamed as Alivus Life Sciences

20 Jan 2025, 10:18 am

Glenmark Life Sciences declare Quarterly Result

On 23 January 2025

17 Jan 2025, 01:55 pm

Glenmark Life Sciences renamed Alivus Life Sciences

With effect from 17 December 2024

17 Dec 2024, 07:43 pm

Alivus Life Sciences Ltd Stock Analysis

Annual revenue for Alivus Life Sciences Ltd increased by 4.80% to ₹2,295.26 crore in FY 2024 from ₹2,190.18 crore in FY 2023.
Annual Net Profit for Alivus Life Sciences Ltd increased by 0.84% to ₹470.89 crore in FY 2024 from ₹466.96 crore in FY 2023.
Promoter Shareholding in Alivus Life Sciences Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in September 2024 to 75% in December 2024.
Alivus Life Sciences Ltd delivered a 1-year return of 48.32% compared to the Nifty 50, which provided a return of 5% as of the last trading session.
Alivus Life Sciences Ltd share price moved up by 4.89% from its previous close of INR ₹1,080.55. The latest Alivus Life Sciences Ltd share price is INR ₹1,133.40.
Alivus Life Sciences Ltd share price today has been at a low of 1,075.35 and a high of 1,136.80. Over the past 52 weeks, the Alivus Life Sciences Ltd share price has seen a low of 719.75 and a high of 1,335.10.